article thumbnail

Cosmetic Dermatology in the Digital Age: How to Harness Technology and Uphold Safety and Ethics

The Dermatology Digest

Cosmetic dermatologists must learn to harness technology while upholding the core values of safety, ethics, and patient satisfaction, writes Neelam Vashi, MD, an Associate Professor of Dermatology at Boston University Chobanian & Avedisian School of Medicine in Boston, MA, in the Journal of Clinical Medicine.

Ethics 74
article thumbnail

Analyzing Efficacy and Safety in Diverse Clinical Trials: New Roflumilast Data

Dermatology Times

After releasing promising data from several clinical trials, Burnett discussed the importance of studying efficacy and safety across diverse populations.

Safety 74
article thumbnail

New Five-year Study Backs Deucravacitinib’s Safety and Efficacy in PsO

The Dermatology Digest

Deucravacitinib (Sotyktu, Bristol Myers Squibb) showed consistent safety and efficacy in patients with in moderate-to-severe plaque psoriasis for up to five years, new research shows. Moreover, the safety profile of deucravacitinib remained consistent through five years with no new safety signals identified.

Safety 36
article thumbnail

Phase 3 Data: “Game-changing” Oral IL-23 Blocker Shows Efficacy and Safety in PsO

The Dermatology Digest

No safety signals emerged through Week 24. “It’s an oral drug that will rival biologics in efficacy,” says study author Jennifer Soung, MD, a Dermatologist and Director of Clinical Research at Southern California Dermatology in Los Angeles, CA.

Safety 36
article thumbnail

U.S. FDA Approves Celltrion’s STELARA Biosimilar

The Dermatology Digest

The clinical results demonstrated that STEQEYMA and its reference product, ustekinumab, are highly similar, and have no clinically meaningful differences in terms of safety and efficacy. “STEQEYMA is now the latest biologic in our immunology portfolio, joining ZYMFENTRA (infliximab-dyyb).

article thumbnail

Navigating Pregnancy, Dermatology, and Drug Safety

Dermatology Times

Katherine Economy, MD, discusses the challenges and opportunities of treating pregnant patients with dermatologic conditions, emphasizing the importance of comprehensive medication reviews, patient-centered decision-making, and the need for including pregnant patients in clinical trials.

Safety 77
article thumbnail

Incyte’s Povorcitinib Hits Primary Endpoints in Phase 3 HS Studies

The Dermatology Digest

Povorcitinib (INCB54707) is an oral small-molecule Janus kinase (JAK) 1 inhibitor currently in Phase 3 clinical trials for HS, vitiligo and prurigo nodularis (PN), as well as Phase 2 trials for asthma and chronic spontaneous urticaria (CSU). The overall safety profile of povorcitinib is consistent with previous data. 75mg: 40.6%

Safety 36